Premium
The European Sero‐Epidemiology Network 2: standardization of assay results for hepatitis B virus
Author(s) -
Kafatos G.,
Anastassopoulou C.,
Nardone A.,
Andrews N.,
Barbara C.,
Boot H. J.,
Butur D.,
Davidkin I.,
Gelb D.,
Griskevicius A.,
Hesketh L.,
Icardi G.,
Jones L.,
KraOz Z.,
Miller E.,
Mossong J.,
Nemecek V.,
De Ory F.,
Sobotová Z.,
Thierfelder W.,
Van Damme P.,
Hatzakis A.
Publication year - 2007
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/j.1365-2893.2006.00789.x
Subject(s) - hbsag , standardization , serology , hepatitis b virus , medicine , virology , vaccination , epidemiology , hepatitis b , population , immunology , antigen , antibody , virus , environmental health , political science , law
Summary. The aim of the European Sero‐Epidemiology Network 2 was to coordinate and standardize the serological surveillance of vaccine‐preventable diseases in Europe. In this study, the standardization of hepatitis B virus (HBV) results is described. The 15 participating national laboratories tested a unique panel of 172 sera established by the Greek reference centre for HBV surface antigen (HBsAg), antibodies to HBsAg (anti‐HBs) and/or to the HBV core antigen (anti‐HBc) by assay methods of their choice. Country‐specific quantitative measurements for anti‐HBs and anti‐HBc were transformed into common units using standardization equations derived by regressing each country's panel results against the reference centre's results, thus adjusting for interassay and interlaboratory variability. For HBsAg, a qualitative analysis (positive/negative) showed at least 99% agreement with the reference laboratory for all countries. By combining these standardized and qualitative results for the markers mentioned earlier, it was possible to achieve comparable estimates of the proportion of the population susceptible to HBV, vaccinated against HBV, with a past HBV infection, and with a current infection or chronic carrier state. Standardization is a very important tool that allows for international serological comparisons to assess the current vaccination policies and the progress of HBV control in Europe.